GSK3858279 is a high-affinity, first-in-class, monoclonal antibody, binding specifically to CCL17 and inhibiting downstream signaling. In this phase I, randomized, single-center, double-blind, placebo-controlled, three-period, incomplete-block crossover study (NCT04114656), the a...
GSK3858279 is a novel, high affinity, human mAb that functionally inhibits CCL17. Objectives To present efficacy, safety, pharmacokinetic (PK) and immunogenicity data from Part B of a first-in-human, 2 part, phase I, randomized, double-blind, placebo (PBO)-controlled study evaluating GSK...